FMTX - FMTX STOCK NEWS

Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) is set to release its first quarter 2022 financial results on May 6, 2022. The company specializes in developing treatments for sickle cell disease, prostate cancer, and other rare hematologic conditions. An investment community conference call will occur at 8 a.m. EDT on the same day to discuss these results and provide an updated business overview. Investors can join the call via specific dialing options or through a live webcast available on Forma's website.

Forma Therapeutics, focused on rare hematologic diseases, announced its financial results for 2021, reporting a net loss of $173 million compared to $70.4 million the previous year. The company successfully completed a Phase I trial of etavopivat for sickle cell disease, showing improved hematologic biomarkers and tolerability. Initial results from FT-7051 in metastatic prostate cancer demonstrate safety and clinical activity. With nearly $490 million in cash, Forma has a financial runway through Q3 2024, enabling ongoing and upcoming clinical trials in SCD and prostate cancer.

Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) will release its fourth quarter and year-end 2021 financial results on March 1, 2022, at 8 a.m. EST. The company focuses on developing therapies for sickle cell disease, prostate cancer, and other rare diseases. Following the results, management will host a conference call to discuss the findings and provide updates on their business strategies. Investors can join via phone or through a live webcast on the company's website.

Forma Therapeutics (Nasdaq: FMTX), a clinical-stage biopharmaceutical company, announced its participation in the virtual 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022. Forma will present on February 16, 2022, at 11:20 a.m. EST. The conference highlights the company’s focus on developing therapies for sickle cell disease, prostate cancer, and other rare hematologic conditions. A webcast of the presentation can be accessed through the "News & Investors" section of Forma's website.

Forma Therapeutics (NASDAQ: FMTX) announced the election of Dr. Arturo Molina to its board of directors and R&D committee. Dr. Molina, with over 25 years in hematology and oncology, is currently the Chief Medical Officer at Sutro Biopharma. His extensive experience includes leadership roles at Johnson & Johnson and Biogen. The company aims to leverage his expertise during its growth phase as it focuses on developing treatments for rare hematologic diseases and cancers. The leadership change is expected to strengthen the company's strategic direction and patient-focused mission.

Forma Therapeutics, a clinical-stage biopharmaceutical company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 a.m. EST. The company focuses on developing therapeutics for sickle cell disease, prostate cancer, and other rare hematologic diseases. A webcast of the presentation will be available on their website. Forma aims to transform patient lives by creating drug candidates that address high unmet needs, leveraging deep biological insight and clinical development expertise.

Forma Therapeutics (NASDAQ: FMTX) announced promising Phase 2 trial results for olutasidenib combined with azacitidine, showing durable complete remission (CR) in acute myeloid leukemia (AML) patients with mIDH1 mutations. Presented at the 2021 ASH Annual Meeting, the study reported a CR/CRh rate of 45% for treatment-naïve patients and 38%-47% for those with relapsed AML. Olutasidenib demonstrated favorable tolerability, with a safety profile consistent with prior findings. These results may position olutasidenib as a viable therapy option in AML management.

Forma Therapeutics, focused on sickle cell disease, presented positive Phase 1 trial results for etavopivat at the ASH Annual Meeting on Dec. 11, 2021. The trial involved 15 patients who received etavopivat for up to 12 weeks, demonstrating sustained increases in hemoglobin (73.3% of patients) and improved red blood cell health while significantly reducing vaso-occlusive crises, with an annualized rate of 0.3 compared to 0.93 pre-treatment. Etavopivat showed a favorable safety profile, with most adverse events being grade 1 and 2. The company continues its Phase 2/3 Hibiscus Study for further assessment.

Forma Therapeutics (NASDAQ: FMTX) announced a commitment of $1M for formabridge grants to support programs aiding the transition from pediatric to adult care in sickle cell disease (SCD). A recent survey revealed that 62% of patients find this transition challenging, with 73% of physicians noting a lack of guidelines. The new resource hub aims to provide essential information for patients and caregivers. Forma's efforts are directed at addressing significant care gaps during this crucial transition period, aiming for improved health outcomes.